Understanding Immunosuppressive Myeloid Cells and Immunotherapy Using Proteome Profiler Antibody Arrays
Jan 29, 2018
Although immune checkpoint blockade is an effective therapeutic intervention for a variety of cancers, it is less effective against metastatic castration-resistant prostate cancer (mCRPC). To address this challenge, Dr. Xin Lu and his colleagues tested the hypothesis that immune checkpoint blockade (ICB) paired with the inhibition of the phosphoinositide 3-kinase (PI 3-K) pathway is a superior therapeutic intervention to ICB alone. Watch this video to see how they used Proteome Profiler™ Antibody Arrays to evaluate signaling in the context of combination therapy.